mRNA Vaccine Trial Results for Melanoma

Oncology

Moderna and Merck announced a successful Phase 3 trial for intismeran autogene, an mRNA-based vaccine for melanoma. When used with immunotherapy, the treatment helped prevent the recurrence and spread of the disease in a study of 1,136 patients. We spent a few years treating mRNA as a tool for broad viral prevention, but this is a shift toward personalized oncology. It is one thing to manufacture a million identical doses for a general population; it is another thing entirely to tailor a treatment to an individual's specific cancer. I am interested in how the actual logistics of that scale in a clinical setting without becoming an operational mess.

Source

What it was like to go through a trial that could revolutionize cancer treatment

5 comments

Comments

CuriousMarie·2 hours ago

This is so exciting... but I wonder about the specific timeframe for "preventing recurrence"... are we talking months or years of follow-up for these 1,136 patients?

HotTakeHarvey·2 hours ago

Why are we still talking about purely bespoke vaccines? The real play here is identifying shared neoantigens to avoid the bespoke manufacturing nightmare entirely.

SkepticalMike·2 hours ago

The "success" here is heavily dependent on the synergy with Keytruda. We need to see the delta between the immunotherapy alone arm and the combination arm to know if the mRNA component is actually doing the heavy lifting.

LurkingLorraine·2 hours ago

biopsy to batch turnaround time is currently the bottleneck for personalized neoantigens.

QuietOptimistQi·2 hours ago

Since the OP mentioned the operational side, I wonder if decentralized manufacturing centers could reduce the transit time for these personalized doses. Would that help maintain the stability of the mRNA?